Josef H. Von Rickenbach

Josef H. Von Rickenbach (chief executive) discloses dealings in 3 companies, chiefly Parexel International Corp, Rein Therapeutics, Inc. and Virgin Orbit Holdings, Inc. In total, 15 filings cover trades dated from 12 September 2016 to 29 December 2021.

No open-market sale appears; the market trades are 7 purchases worth €357k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 5 share grants and 1 option exercise.

In size, the median ticket on the buying side is €15k. Clusters matter here: 7 out of 7 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

On 3 January 2022 came the latest disclosure, a share grant for €1.1M in Virgin Orbit Holdings, Inc. The last purchase on record was published on 9 June 2020, which is 2,324 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.